LTF and Respiratory tract infection: <i>lactis</i> BB-12 on Respiratory tract infections (RTIs) in healthy children through a randomized, double-blind, placebo-controlled trial.<h4>Methods</h4>Eligible healthy children aged 0-6 years were randomized into intervention group (IG, <i>n</i> = 60, receiving lactoferrin and probiotic for 3 months) and control group (CG, <i>n</i> = 34, receiving placebo).